Photo Gallery



News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • MAY 2020 Issue has been successfully launched on 1 May 2020.



Nidhi Gairola* and Prof. Dr. Preeti Kothiyal


Alzheimer's disease (AD) is a common neurodegenerative disorder with age. It is also common cause of dementia.Over the past 20 years, both pharmacological and lifestyle interventions have been studied for its prevention, but the overall results have not been worthy enough. Its pharmacological treatment based on the use of acetylcholinesterase inhibitors, which have beneficial effects on itscognitive, functional, and behavioural symptoms, but their role in AD pathogenesis is unknown. Other available pharmacological therapies is: Drug Memantine (recently approved) which is an NMDA channel blockerfor advanced AD. Here, we will review clinical features &pharmacological propertiesof the available cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) including their evidence for switching from one agent to another, "head to head" studies, and the emerging evidence for the use of memantine in AD. The new therapeutic approach, which closely target the pathogenesis of disease, will be scrutinize.These disease(potential) modifying treatments include amyloid-beta-peptide vaccination, secretase inhibitors, cholesterol-lowering drugs, metal chelators, and anti-inflammatory agents. The objective here is to provide a systematic review of the ongoing evidence pertaining to the use of medicinal herbs and current research in the treatment of Alzheimer's disease (AD) and its associated symptoms. In this review, authors will also discusses about the different aspects of pathophysiological mechanisms behind Alzheimer’s disease and its management through a conventional drug therapy & modern investigational therapeutic strategies that are ongoing or recently completed.

Keywords: Alzheimer's Disease, Acetylcholinesterase Inhibitors, Amyloid-Beta-Peptide, Medicinal Herb.

[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More